STRIDES PHARMA STOCK
Quant Small Cap Fund exits ICICI Bank and 5 others, reduce stake in Zydus Wellness and 5 more in September
Quant Small Cap Fund exited ICICI Bank and five other stocks in September while trimming its holdings in six stocks, including Zydus Wellness. The fund also added six new stocks to its portfolio and increased its stake in 10 others, according to its monthly portfolio disclosure.
JioBlackRock Flexi Cap Fund exits NALCO, Hindustan Zinc; trims exposure in BSE, RIL
JioBlackRock Flexi Cap Fund reshuffled its portfolio in August, exiting 21 stocks while reducing exposure to 34 others, including NALCO, Hindustan Zinc and RIL. It increased holdings in 17 stocks and added 22 new names. The fund’s portfolio grew to 136 stocks, with banks accounting for its largest sector allocation.
Quant Small Cap Fund exits SBI Funds Management, Jubilant FoodWorks and 4 other stocks in August
Quant Small Cap Fund, managed by Quant Mutual Fund, exited six stocks and added four new names in August 2026. The fund increased exposure to 12 stocks while reducing holdings in seven others. Its portfolio stood at 104 stocks, with HFCL commanding the highest allocation at 6.70%. The fund’s AUM rose to Rs 35,557 crore during the month.
Strides Pharma Science shares jump 9% after USFDA EIR for Bengaluru facility
Strides Pharma Science shares rise sharply on Thursday after the USFDA issued an Establishment Inspection Report (EIR) for its Bengaluru facility, concluding a recent cGMP inspection. The inspection ended with five observations, which the company addressed through corrective actions. The regulatory closure offers relief after the stock’s recent weakness.
Stock Radar: Strides Pharma stock hits fresh 52-week high in July; will the rally continue in August?
Strides Pharma Science Limited stock shows positive momentum. It broke a one-month consolidation in July 2025. Experts suggest a buy for a target of Rupees 975 to Rupees 1030. This is expected over the next one to two months. The stock recently reclaimed its 200-DMA. Analysts advise a stop loss at Rupees 895. The stock exhibits strength with bullish indicators.
Stock Radar: Strides Pharma breaks out from 7-month consolidation to hit fresh 52-week high; time to buy?
Strides Pharma Science stock shows positive movement. It broke a seven-month consolidation phase. Experts suggest a buy with a target of Rs 960 in 1-2 months. The stock demonstrated strong momentum, breaking resistance at Rs 760. Technical indicators support a bullish outlook. A stop loss is advised at Rs 750 for risk management. Market participation has increased.
- Go To Page 1
Stock Radar: This pharma stock gave multibagger returns in the last 1 year; should you buy, sell or hold Strides Pharma?
Strides Pharma Science Ltd (STAR) surged over 200% in a year, hitting Rs 1,675 in October. After a dip, the stock rebounded from its 20-week EMA, signaling bullish momentum. Experts predict a target of Rs 1,950 in the coming weeks, with a stop loss at Rs 1,500.
Strides secures shareholders' nod for OneSource specialty CDMO unit
Strides Pharma Science has received approval from shareholders and secured creditors to create OneSource, a specialty pharma CDMO. The company will now seek final approval from the NCLT, Mumbai Bench, and listing approvals from BSE and NSE. This move aims to unlock value for stakeholders upon OneSource's listing.
Stock Radar: This pharma stock sees mild consolidation after 130% rally in 1 year; time to buy the dip?
The pharma stock is a part of the S&P BSE Smallcap index. It saw an uptrend, rising from Rs 393 as of June 9, 2023, to Rs 901 recorded on June 10, 2024. It has, however, undergone mild consolidation of approximately 100 points since April on the daily chart. The stock is in recovery mode with chances of momentum to continue are moderate. Short-term traders can look to accumulate the stock on dips.
Buy Strides Pharma Science, target price Rs 630: Prabhudas Lilladher
Promoters held 28.07 per cent stake in the company as of 30-Jun-2023, while FIIs owned 16.72 per cent, DIIs 19.59 per cent.
Reduce Strides Pharma Science, target price Rs 495: ICICI Securities
Strides Pharma Science Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 4766.18 Crore) operating in Pharmaceuticals sector.
Strides Pharma shares fall over 3% on plans to spin off CDMO, gelatin businesses
As per Trendlyne data, the average target price of Strides Pharma is Rs 530, which shows a downside of 2% from the current market prices. The consensus recommendation from 3 analysts for the stock is a 'Buy'.
Strides Pharma to spin off CDMO assets to form a separate unit
Pharmaceutical company Strides Pharma is planning to demerge its contract development and manufacturing services (CDMO) assets into an associate company called Stelis Biopharma. The new company, named OneSource, will focus on biologics, complex injectables, and soft gelatin capsules. Shareholders of Strides Pharma will receive one share of OneSource for every two shares they hold, giving them a 44% stake in the new company. The demerger will reduce Strides Pharma's debt by $35 million.
Strides Pharma announces business rejig. Shares end 7% up, hit 52 week high
The announcement was made by the company ahead of the market closing. The stock settled at Rs 536 on the NSE, up Rs 37, or 7% over Friday's closing price. Strides Pharma Science shares also hit their 52-week high of Rs 539.
Smallcap pharma stock jumps over 11% as arm receives tentative USFDA approval for HIV drug Dolutegravir
The company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with the USFDA, of which 230+ ANDAs have been approved. The company is eyeing around 60 new product launches over the next three years in the US.
Buy Strides Pharma Science, target price Rs 500: ICICI Securities
Strides Pharma Science Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 3085.64 Crore) operating in Pharmaceuticals sector.
Buy Strides Pharma Science, target price Rs 402: ICICI Securities
Strides Pharma Science Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 3026.83 Crore) operating in Pharmaceuticals sector.
Accumulate Strides Pharma Science, target price Rs 355: Geojit
Strides Pharma Science Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 2836.92 Crore) operating in Pharmaceuticals sector.
Strides Pharma Science Q3 net declines 69% to Rs 92 crore
The consolidated income of the company increased to Rs 744.66 crore in the Oct-Dec period.
Buy Strides Pharma Science, target Rs 472: ICICI Securities
Strides Pharma Science is a midcap company, operating in pharmaceuticals and health care sector.
Strides Pharma Science to get USD 20 mn funding for consumer healthcare business
Drug firm Strides Pharma Science Wednesday said it has partnered with funds advised by ICP-III Investment Advisors, which will infuse USD 20 million into its consumer healthcare business.
Sell Strides Pharma Science, target Rs 405: Manas Jaiswal
Sell Strides Pharma Science at a price target of Rs 405 and a stop loss at Rs 451 from the entry point.
Strides Shasun rallies 2% on USFDA drug approval
The company has 74 cumulative ANDA filings with the USFDA.
Expect midcap pharma stocks to perform well in 2016: Deepak Shenoy.
Shenoy prefers midcap pharma stocks such as Strides Shasun and Torrent Pharma. The expert believes that largecaps will take some time to recover.
Buy pharma stocks on declines: P Phani Sekhar, Angel Broking
Things have been good for some midcap pharma companies. Although they remained midcap in their classification but revenues have almost started touching $1 billion.
Sun Pharma, Cipla best bet among pharma stocks: Sajiv Dhawan
Most of the times these stocks will trade in a range. It is not a sector that I say would outperform even in the next year or so.
Buy Strides Arcolab from a long term perspective: Sonam Udasi
"If you have a long term, go for stocks like Strides Arcolab even Aurobindo Pharma after that huge correction we saw."
Strides Arcolab & Aurobindo Pharma are good stocks to own: Satish Betadpur
Satish Betadpur, CFA, Global Research Director, Independent International Investment Research PLC in an interview with ET Now talks about Strides Arcolab & Aurobindo Pharma.
Load More
